Literature DB >> 16707604

Prognostic significance of activated AKT expression in soft-tissue sarcoma.

Yasuhiko Tomita1, Takaya Morooka, Yoshihiko Hoshida, Binglin Zhang, Ying Qiu, Itsuko Nakamichi, Ken-Ichiro Hamada, Takafumi Ueda, Norifumi Naka, Ikuo Kudawara, Katsuyuki Aozasa.   

Abstract

PURPOSE: AKT is a serine/threonine kinase which is important in tumorigenesis. Several molecules involved in AKT pathway are dysregulated in various kinds of human cancers. PATIENTS AND METHODS: Ninety-three patients (53 males and 40 females), ages ranging from 19 to 77 years (median, 57 years), with localized soft-tissue sarcomas arising in the trunk and extremities, were analyzed. Immunoperoxidase procedure (avidin-biotin complex method) was done on paraffin-embedded sections with anti-phosphorylated AKT (Thr308), anti-phosphorylated p44/42 extracellular signal-regulated kinase 1 and 2 (ERK1/2) (Thr202/Tyr204), anti-phosphorylated forkhead in rhabdomyosarcoma (FKHR) (Ser256), and anti-Ki 67 antibodies. Expression levels of phosphorylated AKT (p-AKT), phosphorylated ERK1/2 (p-ERK1/2), and phosphorylated FKHR (p-FKHR) were categorized as either weaker (level 1) or equal to or stronger (level 2) compared with those in the endothelial cells of the same specimens. Percentage of cells showing intranuclear staining with Ki-67 was shown as the Ki-67 labeling index (LI). Cases were divided into two groups: level 1, Ki-67 LI < 20%; level 2, Ki-67 LI > or = 20%.
RESULTS: Twenty-six (28.0%), 6 (6.5%), and 46 (44.1%) of the tumors showed level 2 expression for p-AKT, p-ERK1/2, and Ki-67 LI, respectively. Tumors with level 2 p-AKT expression showed a higher ratio of level 2 p-FKHR expression (P < 0.01). Multivariate analysis revealed p-AKT expression and Ki-67 LI to be independent prognosticators for overall survival, and p-AKT expression for disease-free survival.
CONCLUSION: p-AKT expression level is a significant prognosticator in soft-tissue sarcoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16707604     DOI: 10.1158/1078-0432.CCR-05-1732

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  25 in total

1.  Axl gene knockdown inhibits the metastasis properties of hepatocellular carcinoma via PI3K/Akt-PAK1 signal pathway.

Authors:  Jingchao Xu; Li Jia; Hongye Ma; Yanping Li; Zhenhai Ma; Yongfu Zhao
Journal:  Tumour Biol       Date:  2013-12-18

2.  Suppression of breast cancer proliferation and induction of apoptosis via AKT and ERK1/2 signal transduction pathways by synthetic polypeptide derived from viral macrophage inflammatory protein II.

Authors:  Qingling Yang; Changjie Chen; Zhifeng Yang; Yangjun Gao; Jie Tang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-08-07

3.  Activation of the Akt-mTOR and MAPK pathways in dedifferentiated liposarcomas.

Authors:  Takeaki Ishii; Kenichi Kohashi; Kunio Iura; Akira Maekawa; Hirofumi Bekki; Yuichi Yamada; Hidetaka Yamamoto; Kazuki Nabeshima; Hiroyuki Kawashima; Yukihide Iwamoto; Yoshinao Oda
Journal:  Tumour Biol       Date:  2015-10-30

4.  Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers.

Authors:  Yoshifumi Baba; Katsuhiko Nosho; Kaori Shima; Marika Hayashi; Jeffrey A Meyerhardt; Andrew T Chan; Edward Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

5.  p-AKT overexpression in primary renal cell carcinomas and their metastases.

Authors:  Martina Hager; Heike Haufe; Lukas Lusuardi; Nikolaus Schmeller; Christian Kolbitsch
Journal:  Clin Exp Metastasis       Date:  2010-09-16       Impact factor: 5.150

6.  PI3K/Akt pathway activation attenuates the cytotoxic effect of methyl jasmonate toward sarcoma cells.

Authors:  Uri Elia; Eliezer Flescher
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

7.  Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.

Authors:  Karen Fernandez; Yelda Serinagaoglu; Sue Hammond; Laura T Martin; Paul T Martin
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

8.  Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases.

Authors:  Argun Akcakanat; Aysegul Sahin; Alexandra N Shaye; Marco A Velasco; Funda Meric-Bernstam
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

9.  Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha.

Authors:  Quan-Sheng Zhu; Wenhong Ren; Borys Korchin; Guy Lahat; Adam Dicker; Yiling Lu; Gordon Mills; Raphael E Pollock; Dina Lev
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

10.  Prognostic significance of MTOR pathway component expression in neuroendocrine tumors.

Authors:  Zhi Rong Qian; Monica Ter-Minassian; Jennifer A Chan; Yu Imamura; Susanne M Hooshmand; Aya Kuchiba; Teppei Morikawa; Lauren K Brais; Anastassia Daskalova; Rachel Heafield; Xihong Lin; David C Christiani; Charles S Fuchs; Shuji Ogino; Matthew H Kulke
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.